Reset filter
Palavras-chave
Infektion ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

49 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Safety and efficacy of topical Retapamulin Ointment vs. oral Linezolid in Secondarily-Infected Traumatic Lesions and Impetigo due to MRSA, NCT00852540 - Eligibility criteria

- 07/03/2019 - 1 Formulário, 4 Grupos de itens, 30 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Eligibility question, Inclusion criteria, Exclusion criteria
Study ID: 110978 Clinical Study ID: 110978 Study Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00852540 https://clinicaltrials.gov/ct2/show/NCT00852540 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Retapamulin Ointment, Oral Linezolid Trade Name: N/A Study Indication: Skin Infections, Bacterial The study consists of 5 vists. The studys period extends over 19 days: Visit 1 (Day 1): Baseline (for both, topical and oral visit) Visit 2 (Day 3-4): On-Therapy (for both, topical and oral visit) Visit 3 (Day 7-9): End of Therapy for topical visit, On-Therapy for oral visit. Visit 4 (Day 12-14): Follow-up for topical visit, End of Therapy for oral visit. Visit 5 (Day 17-19): Final Follow-up for topical visit, Follow-up for oral visit. This document contains the eligibility criteria form. It has to be filled in for screening.

Safety and efficacy of topical Retapamulin Ointment vs. oral Linezolid in Secondarily-Infected Traumatic Lesions and Impetigo due to MRSA, NCT00852540 - Log status

- 04/03/2019 - 1 Formulário, 2 Grupos de itens, 4 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Log status
Study ID: 110978 Clinical Study ID: 110978 Study Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00852540 https://clinicaltrials.gov/ct2/show/NCT00852540 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Retapamulin Ointment, Oral Linezolid Trade Name: N/A Study Indication: Skin Infections, Bacterial The study consists of 5 vists. The studys period extends over 19 days: Visit 1 (Day 1): Baseline (for both, topical and oral visit) Visit 2 (Day 3-4): On-Therapy (for both, topical and oral visit) Visit 3 (Day 7-9): End of Therapy for topical visit, On-Therapy for oral visit. Visit 4 (Day 12-14): Follow-up for topical visit, End of Therapy for oral visit. Visit 5 (Day 17-19): Final Follow-up for topical visit, Follow-up for oral visit. This document contains the Log status form. It has to be filled in for the end of study.

Safety and efficacy of topical Retapamulin Ointment vs. oral Linezolid in Secondarily-Infected Traumatic Lesions and Impetigo due to MRSA, NCT00852540 - Serious Adverse Events (SAE)

- 04/03/2019 - 1 Formulário, 13 Grupos de itens, 58 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Randomisation, Serious Adverse Events, Intensity changes, SAE, Seriousness, SAE, Relevant concomitant medications/treatment medications, Relevant medical conditions/risk factors, SAE, Relevant diagnostic results, SAE, Rechallenge, SAE, Investigational Product 1, Investigational Product 2, Investigational Product 3, General narrative comments
Study ID: 110978 Clinical Study ID: 110978 Study Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00852540 https://clinicaltrials.gov/ct2/show/NCT00852540 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Retapamulin Ointment, Oral Linezolid Trade Name: N/A Study Indication: Skin Infections, Bacterial The study consists of 5 vists. The studys period extends over 19 days: Visit 1 (Day 1): Baseline (for both, topical and oral visit) Visit 2 (Day 3-4): On-Therapy (for both, topical and oral visit) Visit 3 (Day 7-9): End of Therapy for topical visit, On-Therapy for oral visit. Visit 4 (Day 12-14): Follow-up for topical visit, End of Therapy for oral visit. Visit 5 (Day 17-19): Final Follow-up for topical visit, Follow-up for oral visit. This document contains the Serious Adverse Events (SAE) form. It has to be filled in if a SAE occurs during study.

Eligibility HCMV Infection NCT01113359

- 27/12/2018 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
The Link Between Human Cytomegalovirus (HCMV) and Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT01113359

Safety, tolerability, excretion balance and pharmacokinetics of Losmapimod in healthy males, NCT00599612 - Tobacco use, HIV screen

- 04/12/2018 - 1 Formulário, 3 Grupos de itens, 6 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, HISTORY OF TOBACCO USE, SEROLOGY - HIV SCREEN
Study ID: 107806 Clinical Study ID: RA3107806 Study Title: An open label study to determine the safety, tolerability, excretion balance and pharmacokinetics of Losmapimod, administered as a single dose of an oral solution to healthy adult male subjects Patient Level Data: Clinicaltrials.gov Identifier: NCT00599612 https://clinicaltrials.gov/ct2/show/NCT00599612 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: losmapimod Trade Name: losmapimod Study Indication: Pulmonary Disease, Chronic Obstructive The study consists of a screening, study visit and follow-up. The protocol identifier for all: RA3107806 This document contains the history of tobacco use and the serology - HIV screen form. It has to be filled in for screening.

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Medical Conditions, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically Transferred Lab Data - Screening

- 21/11/2018 - 1 Formulário, 11 Grupos de itens, 34 Elementos de dados, 1 Idioma
Grupos de itens: Medical Conditions - Cardiac Disorders, Medical Conditions - Endocrine Disorders, Medical Conditions - Eye Disorders, Medical Conditions - Vascular Disorders, Medical Conditions - Metabolism and Nutrition Disorders, Medical Conditions - Infections and Infestations, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically transferred lab data
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Infection Summary (Visit 8)

- 18/08/2018 - 1 Formulário, 5 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: Administrative, Invasive infection, Blood culture, Anti- infective, Anti-Infective Agents
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infection Summary

- 12/08/2018 - 1 Formulário, 4 Grupos de itens, 19 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Communicable diseases, Infection; Laboratory culture, Anti-infectives
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Please record all presumed and confirmed invasive infections through the Week 13 visit. Record only one infection per form.

Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664 - Infection Summary, Concomitant medications and Transfusions

- 24/05/2018 - 1 Formulário, 2 Grupos de itens, 24 Elementos de dados, 1 Idioma
Grupos de itens: Infection Summary, Concomitant Medications & Transfusions
https://clinicaltrials.gov/show/NCT00989664 Infection Summary, Concomitant medications and Transfusions Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

HIV HPV vaccine NCT00513526 AMC-052 - History of AIDS Defining Disease

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: History of AIDS-defining condition
AMC-052 History of AIDS Defining Disease Form (F03) Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection https://clinicaltrials.gov/ct2/show/NCT00513526 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3953A5F2-81C4-5D54-E044-0003BA3F9857

Eligibility Haemophilus Influenzae Type B NCT00441012

- 11/04/2017 - 1 Formulário, 2 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED); ODM derived from: https://clinicaltrials.gov/show/NCT00441012

Eligibility Staphylococcal Infections NCT00211913

- 23/12/2016 - 1 Formulário, 2 Grupos de itens, 12 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
StaphVAX in Cardiovascular Surgery Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00211913

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial